- Rating
- 1
- Confidence
- 4
- Informativeness
- 1
- Presentation
- 3
- Soundness
- 1
Read review
Paper summary
The manuscript proposes a conditional image-generation method for translating between protein markers, using an H&E image as the conditioning input to generate images in other immunohistochemistry (IHC) marker domains. The method incorporates domain-specific information through the pretrained vision–language model PathCLIP, uses single-step generation with discriminators during training to reduce inference time, and introduces a domain-specific hematoxylin-channel regularization loss to preserve relevant morphological features. The authors further propose a two-stage training strategy that first trains at low resolution and then fine-tunes at high resolution to reduce computational cost. The method is evaluated extensively across multiple datasets.
Critical strengths
-
The experimental evaluation is extensive, covering multiple datasets and metrics, with mostly relevant baselines. I particularly value the downstream evaluations in Table 2, which are highly relevant and provide an important result for the paper.
-
The use of domain-specific encoders and the effort to address the inference-latency limitations of diffusion models are both relevant and well motivated.
Critical weaknesses
These are the Critical Weaknesses in my opinion:
-
Novelty. In my view, this is a strong benchmarking paper, but it is not sufficiently novel as a methods paper. Most of the proposed components have either already been used in computational pathology or exist in closely related forms in other domains.
- The hematoxylin-channel loss has previously been proposed and used for virtual staining, some of which have already been referenced in related works. I also have additional concerns regarding this component, which I discuss in the questions section.
- Single-step diffusion with a discriminator may not previously have been applied to pathology, but it has been developed and used in other domains. I am willing to credit the authors for applying this idea in the pathology setting.
- Domain-specific encoders have been used multiple times for virtual staining, including as feature encoders or through representation losses intended to provide more domain-specific information. This component therefore does not appear novel.
- Training at lower resolution followed by fine-tuning at higher resolution is a well-established training paradigm across many domains and applications. It likewise should not be presented as a novel contribution.
Overall, I find the novelty argument of the paper weak. The work feels more like a combination of existing ideas that achieves modest improvements over prior methods, rather than a substantively new methodological contribution.
-
Relevant ablations are missing.
-
The claim in Line 228 does not appear to be sufficiently substantiated. Is it based on an empirical observation, and are there experimental results supporting it? The main relevant evidence seems to be Table 5, which shows that different pathology encoders—UNI-2, Virchow, and PathCLIP—have some effect, but the differences do not appear substantial. It is therefore unclear how strongly the claim can be made.
-
To support the claim that these domain-specific embeddings provide information comparable to that of a seasoned pathologist, it would be valuable to compare them with non-domain-specific encoders, such as ResNet, ConvNeXt, or other general-purpose encoders. If those encoders provide similar benefits, then the claimed importance of domain-specific representations should be tempered and presented more neutrally.
-
-
Missing relevant comparisons.
-
MCS-Stain [1] appears to be the closest GAN-based counterpart, as it uses pathology-pretrained encoders for cell segmentation, yet it is not included in the experimental comparisons.
-
M2PL-GAN [2] also appears to be a relevant baseline for comparison.
-
No Flow based models are included as baselines ? Flow based models tend to match generation capabilities of diffusion models with substantially less inference cost, so those seem as relevant baselines as well.
[1] Hu, Yihuang, et al. “MCS-Stain: Boosting FFPE-to-HE Virtual Staining With Multiple Cell Semantics.” IEEE Transactions on Medical Imaging, 2025.
[2] Liu, Zequn, et al. “M2PL-GAN: Multi-View Multi-Level Pathology Semantic Perception Learning for H&E-to-IHC Virtual Staining.” IEEE Transactions on Medical Imaging, 2026.
- Important results and analysis are confined to the supplementary material. Several central analyses, including the DAB-channel analysis, limitations, and future-work discussion, appear only in the supplementary material and are not referenced in the main paper. As a result, the paper can feel incomplete even when relevant answers exist in the supplement. Since reviewers are not required to review supplementary material, important observations and experiments may be missed. I therefore believe the paper requires substantial restructuring or rewriting to bring its key analyses, limitations, and conclusions into the main paper and sharpen its overall focus.
Questions for authors
Questions for the Authors:
-
Table 3 suggests that removing (L_{\mathrm{LPIPS}}) has the largest effect on performance. However, LPIPS is not pathology-specific; it primarily measures perceptual similarity between source and target images. In contrast, removing the prior or expert component does not appear to reduce performance by a comparably large margin. This raises the question of whether the reported gains are primarily attributable to the pathology-pretrained expert, or instead to the particular combination of losses. For example, would LPIPS combined with the expert component account for most of the improvement?
-
The model rankings in Table 2 do not appear to align with those in Table 1. Higher PSNR or SSIM, and lower KID or FID, do not seem consistently associated with better downstream IHC classification performance. This raises a question about how the two evaluations should be interpreted: if the trends are not correlated, which table should be considered more reliable for judging model quality? At a minimum, the paper should discuss why improved image-similarity metrics do not translate into improved downstream classification performance, identify the limitations of the current evaluation, and clarify how readers should interpret these results with appropriate caution.
-
In the comparison with VIM, which is presented as the closest prior method, is the model trained at (512 \times 512), as in the original paper, or retrained from scratch at (1024 \times 1024) for a fair comparison? Further, what would happen if VIMs were trained at (512 \times 512) and then fine-tuned at (1024 \times 1024), following the proposed two-stage strategy? Would this yield better results and reduce the apparent contribution of the proposed training procedure?
Minor Problems or Suggestions for Improvement:
-
Line 083 states, “The standard benchmark resolution on which GAN …”. This appears overly broad for pathology and conflates image size with image resolution. While many public benchmarks may use (1024 \times 1024)-pixel images, pathology resolution is generally specified in micrometers per pixel and varies with scanner magnification, such as (40\times), (20\times), or (10\times). The statement should be made more precise.
-
The first paragraph of the related-work section, beginning at Line 134, cites recent GAN-based methods from 2024–2026, but then uses a 2022 citation to support the claim that GAN-based generation produces low-quality images. Is this conclusion still justified in light of the newer models cited immediately before it? In addition, the cited study concerns natural images. It is unclear whether the same conclusion can be directly extended to other domains, including pathology, radiology, or MRI, without domain-specific evidence.